You have full text access to this OnlineOpen article

The effects of oxidative stress on parkin and other E3 ligases

  1. Matthew J. LaVoie1,2,
  2. Giuseppe P. Cortese1,
  3. Beth L. Ostaszewski1,
  4. Michael G. Schlossmacher3

Article first published online: 17 AUG 2007

DOI: 10.1111/j.1471-4159.2007.04911.x

Issue

Journal of Neurochemistry

Journal of Neurochemistry

Volume 103, Issue 6, pages 2354–2368, December 2007

Additional Information

How to Cite

LaVoie, M. J., Cortese, G. P., Ostaszewski, B. L. and Schlossmacher, M. G. (2007), The effects of oxidative stress on parkin and other E3 ligases. Journal of Neurochemistry, 103: 2354–2368. doi: 10.1111/j.1471-4159.2007.04911.x

Author Information

  1. 1

    Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Boston, Massachusetts, USA

  2. 2

    Harvard Medical School, Boston, Massachusetts, USA

  3. 3

    Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada

*Address correspondence and reprint requests to Matthew J. LaVoie, PhD, Brigham and Women’s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, HIM 764, Boston, MA 02115, USA. E-mail: mlavoie@rics.bwh.harvard.edu

Publication History

  1. Issue published online: 17 AUG 2007
  2. Article first published online: 17 AUG 2007
  3. Received May 9, 2007; revised manuscript received July 24, 2007; accepted August 9, 2007.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (607K)

References

  • Ardley H. C., Scott G. B., Rose S. A., Tan N. G., Markham A. F. and Robinson P. A. (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol. Biol. Cell 14, 4541–4556.
  • Banker G. and Goslin K. (1996) Culturing Nerve Cells: Cellular and Molecular Neuroscience Series. The MIT Press, Cambridge, MA.
  • Berger Z., Ravikumar B., Menzies F. M. et al. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433–442.
  • Choi P., Ostrerova-Golts N., Sparkman D., Cochran E., Lee J. M. and Wolozin B. (2000) Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport 11, 2635–2638.
  • Choi P., Golts N., Snyder H. et al. (2001) Co-association of parkin and alpha-synuclein. Neuroreport 12, 2839–2843.
  • Choi J., Levey A. I., Weintraub S. T., Rees H. D., Gearing M., Chin L. S. and Li L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J. Biol. Chem. 279, 13256–13264.
  • Chung K. K., Zhang Y., Lim K. L., Tanaka Y., Huang H., Gao J., Ross C. A., Dawson V. L. and Dawson T. M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7, 1144–1150.
  • Chung K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L. and Dawson T. M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304, 1328–1331.
  • Cookson M. R. (2005) The biochemistry of Parkinson’s disease. Annu. Rev. Biochem. 74, 29–52.
  • Crawford G. D. Jr, Le W. D., Smith R. G., Xie W. J., Stefani E. and Appel S. H. (1992) A novel N18TG2 × mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12, 3392–3398.
  • Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295.
  • Dauer W. and Przedborski S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39, 889–909.
  • Dawson T. M. (2006) Parkin and defective ubiquitination in Parkinson’s disease. J. Neural Transm. Suppl. 70, 209–213
  • Farrer M. J.. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306–318.
  • Finn P. F., Mesires N. T., Vine M. and Dice J. F. (2005) Effects of small molecules on chaperone-mediated autophagy. Autophagy 1, 141–145.
  • Greenamyre J. T. and Hastings T. G.(2004) Biomedicine. Parkinson’s-divergent causes, convergent mechanisms. Science 304, 1120–1122.
  • Hastings T. G. and Zigmond M. J. (1997) Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural Transm. Suppl. 49, 103–110.
  • Hattori N., Machida Y., Sato S., Noda K., Iijima-Kitami M., Kubo S. and Mizuno Y. (2006) Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins. J. Neural Transm. Suppl. 70, 205–208
  • Hedrich K., Kann M., Lanthaler A. J. et al. (2001) The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet. 10, 1649–1656.
  • Henn I. H., Gostner J. M., Lackner P., Tatzelt J. and Winklhofer K. F. (2005) Pathogenic mutations inactivate parkin by distinct mechanisms. J. Neurochem. 92, 114–122.
    Direct Link:
  • Hilker R., Klein C., Ghaemi M. et al. (2001) Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann. Neurol. 49, 367–376.
    Direct Link:
  • Hilker R., Klein C., Hedrich K., Ozelius L. J., Vieregge P., Herholz K., Pramstaller P. P. and Heiss W. D. (2002) The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci. Lett. 323, 50–54.
  • Huynh D. P., Scoles D. R., Ho T. H., Del Bigio M. R. and Pulst S. M. (2000) Parkin is associated with actin filaments in neuronal and nonneural cells. Ann. Neurol. 48, 737–744.
    Direct Link:
  • Kahns S., Lykkebo S., Jakobsen L. D., Nielsen M. S. and Jensen P. H. (2002) Caspase-mediated parkin cleavage in apoptotic cell death. J. Biol. Chem. 277, 15303–15308.
  • Kahns S., Kalai M., Jakobsen L. D., Clark B. F., Vandenabeele P. and Jensen P. H. (2003) Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J. Biol. Chem. 278, 23376–23380.
  • Kay D. M., Moran D., Moses L. et al. (2007) Heterozygous parkin point mutations are as common in control subjects as in Parkinson’s patients. Ann. Neurol. 61, 47–54.
    Direct Link:
  • Keller J. N., Huang F. F., Dimayuga E. R. and Maragos W. F. (2000) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic. Biol. Med. 29, 1037–1042.
  • Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608.
  • Klein C. and Schlossmacher M. G. (2006) The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2, 136–146.
  • Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher M. G. and Lang A. E. (2007) Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 6, 652–662.
  • Kubo S. I., Kitami T., Noda S. et al. (2001) Parkin is associated with cellular vesicles. J. Neurochem. 78, 42–54.
    Direct Link:
  • LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G. and Selkoe D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214–1221.
  • Lucking C. B., Abbas N., Durr A. et al. (1998) Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson’s Disease and the French Parkinson’s Disease Genetics Study Group. Lancet 352, 1355–1356.
  • Muqit M. M., Davidson S. M., Payne Smith M. D., MacCormac L. P., Kahns S., Jensen P. H., Wood N. W. and Latchman D. S. (2004) Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin’s effect on neuronal survival. Hum. Mol. Genet. 13, 117–135.
  • Pawlyk A. C., Giasson B. I., Sampathu D. M. et al. (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278, 48120–48128.
  • Reinstein E. and Ciechanover A. (2006) Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann. Intern. Med. 145, 676–684.
  • Rubinsztein D. C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780–786.
  • Schlossmacher M. G., Frosch M. P., Gai W. P. et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655–1667.
  • Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J. and Selkoe D. J. (2001) Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA 98, 9110–9115.
  • Sriram S. R., Li X., Ko H. S., Chung K. K., Wong E., Lim K. L., Dawson V. L. and Dawson T. M. (2005) Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of Parkin. Hum. Mol. Genet. 17, 2571–2586
  • Stokes A. H., Hastings T. G. and Vrana K. E. (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55, 659–665.
    Direct Link:
  • Walter U., Klein C., Hilker R., Benecke R., Pramstaller P. P. and Dressler D. (2004) Brain parenchyma sonography detects preclinical parkinsonism. Mov. Disord. 19, 1445–1449.
    Direct Link:
  • Wang C., Ko H. S., Thomas B. et al. (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum. Mol. Genet. 14, 3885–3897.
  • Webb J. L., Ravikumar B., Atkins J., Skepper J. N. and Rubinsztein D. C. (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013.
  • West A., Periquet M., Lincoln S. et al. (2002) Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet. 114, 584–591.
    Direct Link:
  • Winklhofer K. F., Henn I. H., Kay-Jackson P. C., Heller U. and Tatzelt J. (2003) Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 278, 47199–47208.
  • Yang Y. X., Muqit M. M. and Latchman D. S. (2006) Induction of parkin expression in the presence of oxidative stress. Eur. J. Neurosci. 24, 1366–1372.
    Direct Link:
  • Yao D., Gu Z., Nakamura T. et al. (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl Acad. Sci. USA 101, 10810–10814.
  • Zecca L., Zucca F. A., Wilms H. and Sulzer D. (2003) Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26, 578–580.
View Full Article (HTML) Get PDF (607K)